1. Scrip

Dynacure’s Antisense Approach To Rare Myopathies Gets Funding Boost

Ionis Collaborating On Development

 
• By John Davis

France’s fledgling biotech Dynacure has pulled together a series C funding round to support its ongoing Phase I/II study of an antisense molecule for an ultrarare myopathy.    

Skeletal_Muscle
Skeletal Muscle • Source: Shutterstock

Just four years after inception, the France/US rare diseases start-up Dynacure SAS has raised €50m ($55m) in a series C funding to help support an ongoing Phase I/II trial of its lead antisense candidate, DYN101, in patients with myotubular and centronuclear myopathies (CNMs).

As well as the ongoing trial in adults, the proceeds from the fundraising will also be used to expand the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Ultragenyx and Mereo Still Confident Despite Setrusumab Slip Up

 
• By Kevin Grogan

The osteogenesis imperfecta drug stumbled in a second interim analysis.

Executives On The Move: New CEOs At Outlook Therapeutics And Peptomyc

Recent moves in the industry include C-suite changes at Essential Pharma, plus Kyverna Therapeutics gets new chief financial officer from Alector.

Investors Back Nuclidium’s Next-Gen Copper-Based Radiopharmaceuticals

 
• By Andrew McConaghie

The Swiss company believes its platform can make radiopharmaceuticals easier to produce and more accessible to patients.